Article Text

Download PDFPDF
Antibiotics did not prevent adverse outcomes after preterm, prelabour rupture of fetal membranes

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 QUESTION: In pregnant women with preterm, prelabour rupture of fetal membranes (pPROM), are antibiotics better than placebo for preventing neonatal death, chronic lung disease, or major cerebral abnormality before discharge?


Randomised {allocation concealed*}, blinded (patients and clinicians {outcome assessors and statisticians}),* placebo controlled trial with a median follow up of 4 days.


161 centres in 15 countries.


4826 pregnant women who had fetuses that were <37 weeks of gestation, had pPROM, and had an uncertain need for antibiotics. Women who would have immediate or unstoppable delivery or who had fetuses not premature enough to warrant concern, had medical or drug contraindications, were prescribed antibiotics, or who were to be prescribed antibiotics for infection were excluded. 4809 women (mean age 28 y) were studied after exclusion of 15 women for protocol violations and 2 women for loss to follow up.


1197 women were allocated to erythromycin, 250 mg; 1212 were allocated to co-amoxiclav, 325 …

View Full Text


  • Sources of funding: UK Medical Research Council. Co-amoxiclav (Augmentin) and co-amoxiclav placebo were supplied by SmithKline Beecham; erythromycin (Erymax) and erythromycin placebo were supplied by Parke Davis.

  • For correspondence: Ms S Kenyon, Department of Obstetrics and Gynaecology, Robert Kilpatrick Building, Leicester Royal Infirmary, PO Box 65, Leicester LE2 7LX, UK. Fax +44 (0)116 252 3154.

  • * See glossary.

  • Information provided by author.